In BC, LSD1 and KDM6A have been found to co-express and co-localize with ER, and regulate hormone receptor signaling (Benedetti et al., 2019), suggesting that developing dual-targeting agents against the two proteins are potent strategy to improve the potency of LSD1 inhibitors. Here, KDM6A is linked to breast cancer.